SPOTLIGHT -
Universal screening for HCV infection is cost-effective
Study suggests all adults age 18 and older should be screened for HCV.
Half of hepatitis C patients can receive shorter direct-acting antiviral treatments
Shorter treatment could significantly reduce costs of therapy.
Too few young opioid drug users tested for hepatitis C infection
Effective direct-acting antivirals are available for teens.
Hepatitis C drug treatments effective for inject drug users
Strong evidence supports removal of restrictions to direct-acting antiviral therapy based on recent drug use.
Transplanting Hepatitis C-infected kidneys is cost-effective and safe
Two studies show these kidneys could be valuable resource for patients in need
Drug addicts face barriers that prevent Hepatitis C treatment
New approaches are needed for physicians to engage young people who inject drugs
Hepatitis C epidemic hides within opioid use epidemic
An urgent call to action to treat combined epidemics
Hepatitis C virus eradication by direct-acting antiviral agents improves glucose tolerance
Glucose tolerance is an independent predictor of overall mortality and hepatic decompensation in patients with HCV cirrhosis.
Two-drug direct-acting antiviral combination treats advanced liver disease
Ledipasvir/sofosbuvir is safe and effective for hepatitis C virus patients who fail on simeprevir/ sofosbuvir.
Direct-acting antiviral combination effective in hard-to-treat hepatitis C virus genotype 3
Real-world study shows efficacy of sofosbuvir/velpatasvir for 12 weeks
Direct-acting antiviral combination improves work productivity in chronic hepatitis C patients
Treatment with a combination of ledipasvir and sofosbuvir can lead to large economic gains.
Liver cancer patients should receive direct-acting antivirals with highest response rates
Clinicians need to carefully plan treatment when prescribing DAA therapy for patients infected with hepatitis C virus who have hepatocellular carcinoma.
Direct-acting viral combination safely treats advanced fibrosis and compensated cirrhosis
All hepatitis C virus genotypes respond to therapy
Kidneys infected with hepatitis C safe to transplant
Recipients of hepatitis C-infected kidneys treated with direct-acting antiviral agents are disease-free one year post-transplant.
